Form 4: 10x Genomics Director Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director John R. Stuelpnagel was granted 8,829 restricted stock units as part of his compensation package with 10x Genomics.
Summary
- Director John R. Stuelpnagel acquired 8,829 restricted stock units (RSUs) on June 4, 2026.
- Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
- The RSUs vest in quarterly installments over one year, beginning May 21, 2026, contingent on continued service.
- Following this transaction, the director's total beneficial ownership is 368,436 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard equity grant for a board member.
Risks
- Vesting is subject to the director continuing as a service provider to the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology and life sciences sector to ensure director retention and alignment with company performance.
Comparison to Industry Standards
- The use of quarterly vesting schedules for director RSUs is consistent with standard corporate governance practices for NASDAQ-listed companies.
- The grant size is commensurate with typical non-employee director compensation packages for mid-cap life sciences firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Randy Wu and James Bryant as attorneys-in-fact for SEC filings. | 2026-03-04 | Administrative update to facilitate timely regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard director compensation event.
Next Steps
- Quarterly vesting of the granted RSUs starting from May 21, 2026.
Key Dates
| Date | Description |
|---|---|
| 2026-03-04 | Date of Power of Attorney execution. |
| 2026-05-21 | Start date for RSU vesting schedule. |
| 2026-06-04 | Date of the RSU grant transaction. |
| 2026-06-08 | Date of filing. |
Keywords
10x Genomics, TXG, Form 4, Insider Transaction, Equity Compensation, Director Stock Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.